Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation

Next Previous
Trial Profile

A Double-Blind, Randomized, Active Comparator Study of LT-NS001 Versus Naprosyn for Seven Days in Healthy Subjects With Endoscopic Evaluation

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2010

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naproxen etemesil (Primary) ; Naproxen
  • Indications Musculoskeletal pain; Osteoarthritis; Pain; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Logical Therapeutics

Most Recent Events

  • 20 Nov 2009 Results presented at GASTRO 2009.
  • 20 Oct 2009 Results will be presented at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009, according to a Logical Therapeutics media release.
  • 26 May 2009 Results reported in a Medinox media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top